GHK-Cu Research Overview: The Copper Peptide in Skin, Wound and Gene-Expression Studies
GHK-Cu is unusual among research peptides on three counts: it is a natural human molecule, its research history spans five decades, and it is visibly blue. This overview maps the main research threads.
The molecule
GHK is a tripeptide — glycyl-L-histidyl-L-lysine — first isolated from human plasma in 1973. It binds copper(II) with high affinity to form the GHK-Cu complex, the form in which it circulates and acts. The much-cited aging observation: plasma GHK declines from roughly 200 ng/mL in early adulthood to around 80 ng/mL by age 60 — one reason it became a model compound for skin-aging research.
Main research threads
- Collagen and matrix synthesis — fibroblast studies report increased collagen, glycosaminoglycan and decorin production; this is the foundation of its use in dermatological research.
- Wound models — accelerated closure and improved matrix remodeling in rodent and rabbit wound studies, with copper delivery to the wound bed considered part of the mechanism.
- Gene-expression profiling — the most cited modern work: screening studies (Broad Institute Connectivity Map) reported GHK modulates expression of a substantial fraction of the human genome, including resetting patterns associated with tissue injury toward a regenerative profile. Provocative, but note these are transcriptomic association studies, not outcome trials.
- Cosmetic formulation research — the one commercialized arena: topical GHK-Cu appears in peer-reviewed facial-study literature with reported improvements in skin density and wrinkle depth versus vehicle.
Limits of the evidence
The cell-culture and animal literature is broad; controlled human data beyond topical cosmetic studies is thin. No injectable GHK-Cu product holds approval anywhere. Gene-expression findings, while striking, describe transcriptional associations — not demonstrated clinical effects.
Practical laboratory notes
The copper complex gives solutions a distinct blue color — expected, not a contamination sign. GHK-Cu is stable in aqueous solution by peptide standards but follows normal practice: refrigerate, protect from light, respect the 30-day window. Avoid co-formulating with strong chelators (EDTA), which strip the copper and change the compound under study.
We stock independently tested GHK-Cu (100mg vials), plus the GLOW and KLOW multi-compound research blends that include it. For research use only — not for human or veterinary use.